Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report

• Published in: Frontiers in oncology Vol. 13; p. 1268260
• Main Authors: Xu, Junzhu, He, Bo, Wang, Yunan, Wu, Mengjia, Lu, Yanyi, Su, Zixuan, Liu, Shujun, Yin, Fengmin, Zhou, Jian-Guo, Hu, Wei
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 18.01.2024
• Subjects: ADCS; chemotherapy; HER2 mutation; non-small cell lung cancer; Oncology; T-DXd; target-therapy; non-small cell lung cancer; target-therapy; T-DXd; ADCS; chemotherapy; HER2 mutation
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1268260

Human epidermal growth factor 2 ( ) mutations are uncommon in non-small cell lung cancer (NSCLC), and the lack of established, effective, targeted drugs has resulted in a persistently poor prognosis. Herein, we report the case of a non-smoking, 58-year-old man diagnosed with lung adenocarcinoma (cT3N0M1c, stage IVB) harboring a mutation (Y772_A775dupYVMA) and PD-L1 (-). The patient's Eastern Cooperative Oncology Group performance status (PS) score was assessed as 1. He commenced first-line treatment with chemotherapy, followed by immuno-chemotherapy, and with disease progression, he received HER2-targeted therapy and chemotherapy with an anti-angiogenic agent. However, HER2-targeted therapy, including pan-HER tyrosine kinase inhibitors (afatinib, pyrotinib, and pozitinib) and antibody-drug conjugate (T-DM1), produced only stable disease (SD) as the best response. After the previously described treatment, primary tumor recurrence and multiple brain metastases were observed. Despite the patient's compromised overall physical condition with a PS score of 3-4, he was administered T-DXd in addition to whole-brain radiotherapy (WBRT). Remarkably, both intracranial metastases and primary lesions were significantly reduced, he achieved a partial response (PR), and his PS score increased from 3-4 to 1. He was then treated with T-DXd for almost 9 months until the disease again progressed, and he did not discontinue the drug despite the occurrence of myelosuppression during this period. This is a critical case as it exerted an effective response to T-DXd despite multiple lines therapy, including T-DM1. Simultaneously, despite the occurrence of myelosuppression in the patient during T-DXd, it was controlled after aggressive treatment.